
Mantle Cell Lymphoma
Latest News
Latest Videos

CME Content
More News

Real-world data suggest CD20 bispecific antibodies show activity after CD19 CAR T in mantle cell lymphoma, though durability of response remains unclear.

Ibrutinib plus bendamustine and rituximab prolonged PFS in patients with previously untreated mantle cell lymphoma who achieved a CR.

Ibrutinib plus venetoclax yielded sustained complete response rates and a favorable safety profile in relapsed/refractory mantle cell lymphoma.

Fangfang Yan, PhD, discusses findings from a multi-omic analysis that identified mechanisms of pirtobrutinib resistance in mantle cell lymphoma.

Patients with relapsed/refractory MCL had poor treatment outcomes with BTK inhibition, which decreased in quality as the line of therapy advanced.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data from real-world analysis of treatment patterns in high-risk mantle cell lymphoma and their implications.

Fangfang Yan, MD, discusses the place of CAR T-cell therapy in the MCL treatment paradigm and how AI can address drivers of CAR T-cell therapy resistance.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data with an acalabrutinib-based regimen in high-risk mantle cell lymphoma from the WINDOW-3 trial.

Andre Henri Goy, MD, discusses key developments in mantle cell lymphoma presented at the 2025 ASH Annual Meeting.

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Carlo Visco, MD, discusses phase 2 FIL_V-RBAC results showing venetoclax plus RBAC achieved a meaningful PFS and manageable toxicity in high-risk MCL.

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

Carlo Visco, MD, explains the need to study treatment outcomes and develop novel therapies for patients with mantle cell lymphoma harboring TP53 mutations.

Carlo Visco, MD, highlights the clinical relevance of reducing the dose of certain RBAC components when administering this regimen in high-risk MCL.

Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.

Carlo Visco, MD, discussed patient characteristics, efficacy data, and safety findings from the FIL_V-RBAC study of venetoclax plus RBAC in MCL.

Martin Dreyling, MD, provides recommendations for use of acalabrutinib plus BR in pretreated MCL based on updated data from the phase 3 ECHO trial.


















































